<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01999114</url>
  </required_header>
  <id_info>
    <org_study_id>BUP1025</org_study_id>
    <nct_id>NCT01999114</nct_id>
  </id_info>
  <brief_title>The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (Mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Triple-blind, Placebo- and Positive-Controlled, Parallel Group Study of the Effect of Buprenorphine Delivered by the Buprenorphine Transdermal System (BTDS) at Doses up to 80 Mcg/Hour and Naltrexone on ECG Intervals in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Purdue Pharma LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Purdue Pharma LP</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the ECG effects of 10, 40, and 80 mcg/hr
      buprenorphine delivered by BTDS alone, or by BTDS dosed with naltrexone, relative to placebo
      in healthy male and female subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-matched change from baseline in QT data corrected for heart rate (QTc), placebo-corrected, based on an individual correction (QTcI) method (ΔΔQTcI)</measure>
    <time_frame>Baseline to Day 6</time_frame>
    <description>The ECG effects of 10 mcg/hr buprenorphine (Day 6) delivered by BTDS alone, or by BTDS dosed with naltrexone relative to placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-matched change from baseline in QT data corrected for heart rate (QTc), placebo-corrected, based on an individual correction (QTcI) method (ΔΔQTcI)</measure>
    <time_frame>Baseline to Day 13</time_frame>
    <description>The ECG effects of 40 mcg/hr buprenorphine (Day 13) delivered by BTDS alone, or by BTDS dosed with naltrexone relative to placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-matched change from baseline in QT data corrected for heart rate (QTc), placebo-corrected, based on an individual correction (QTcI) method (ΔΔQTcI)</measure>
    <time_frame>Baseline to Day 17</time_frame>
    <description>The ECG effects of 80 mcg/hr buprenorphine (Day 17) delivered by BTDS alone, or by BTDS dosed with naltrexone relative to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QTcF and QTcB for historical purposes, heart rate (HR), PR interval, QRS interval, uncorrected QT interval, ECG morphology</measure>
    <time_frame>Baseline to Day 6, Day 13, and Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the QTcI change from baseline and maximum observed plasma concentrations (Cmax) of buprenorphine and norbuprenorphine</measure>
    <time_frame>Baseline to end of study</time_frame>
    <description>The relationship between the placebo-corrected (placebo-adjusted) change from baseline in QTc intervals (QTcI, QTcF and QTcB) and plasma concentrations of buprenorphine and its metabolite, norbuprenorphine, with and without naltrexone.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">328</enrollment>
  <condition>ECG Effects</condition>
  <arm_group>
    <arm_group_label>BTDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine transdermal patches 10, 40 (2 x 20) and 80 (4 x 20) mcg/hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BTDS with naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine transdermal patches 10, 40 (2 x 20) and 80 (4 x 20) mcg/hr and naltrexone 50 mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naltrexone 50 mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moxifloxacin 400-mg tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine transdermal patch</intervention_name>
    <description>Buprenorphine transdermal patch applied transdermally for 7-day wear</description>
    <arm_group_label>BTDS</arm_group_label>
    <arm_group_label>BTDS with naltrexone</arm_group_label>
    <other_name>Butrans</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone tablet</intervention_name>
    <description>Naltrexone tablet; 1 tablet taken orally every 12 hours</description>
    <arm_group_label>BTDS with naltrexone</arm_group_label>
    <arm_group_label>Naltrexone</arm_group_label>
    <other_name>ReVia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos (for TDS and for naltrexone and for moxifloxacin)</intervention_name>
    <description>Matching placebos</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin tablet</intervention_name>
    <description>Moxifloxacin tablet; 1 tablet taken orally on Days 6, 13 and 17</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <other_name>Avelox®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent.

          -  Males and females aged 18 to 55, inclusive.

          -  Body weight ranging from 50 to 100 kilograms (kg) (110 to 220 lbs) and body mass index
             (BMI) ranging from 18 to 30 (kg/m2), inclusive.

          -  Healthy and free of significant abnormal findings as determined by medical history,
             physical examination, clinical laboratory values, vital signs, and resting 12-lead
             ECG.

          -  Females of child-bearing potential must be using an adequate and reliable method of
             contraception (ie, barrier with additional spermicidal foam or jelly, intra-uterine
             device, hormonal contraception). Females who are postmenopausal must have been
             postmenopausal ≥ 1 year and have elevated serum follicle stimulating hormone (FSH).

          -  Willing to eat the food supplied during the study.

          -  Willing to refrain from strenuous exercise during the entire study. Subjects will not
             begin a new exercise program nor participate in any unusually strenuous physical
             exertion.

          -  All 8 anatomical transdermal system (TDS) application sites (upper back, upper chest,
             upper outer arm, or lateral thorax) must be acceptable for study use.

        Exclusion Criteria:

          -  Females who are pregnant (positive beta human chorionic gonadotropin test) or
             lactating.

          -  Current or recent (within 5 years) history of drug or alcohol abuse.

          -  History or any current conditions that might interfere with drug absorption
             (transdermal or gastrointestinal), distribution, metabolism or excretion.

          -  Use of an opioid-containing medication in the past 30 days preceding the initial dose
             in this study.

          -  Known allergy to buprenorphine, any excipient of BTDS, opioids, psychotropic or
             hypnotic drugs, and/or moxifloxacin or any member of the quinolone class drugs.

          -  Any history of frequent nausea or emesis regardless of etiology.

          -  Any history of seizures or head trauma with sequelae.

          -  Participation in a clinical drug study during the 30 days preceding the initial dose
             in this study.

          -  Any significant illness during the 30 days preceding the initial dose in this study.

          -  Use of any medication including thyroid hormonal therapy (hormonal contraception and
             hormonal replacement therapy in the form of estrogen with or without progestin is
             allowed), vitamins, herbal and/or mineral supplements during the 7 days preceding the
             initial dose.

          -  Any personal or family history of prolonged QT interval or disorders of cardiac
             rhythm.

          -  Abnormal cardiac conditions including hypertension.

          -  Abnormal cardiac condition denoted by any of the following:

               -  QTcF interval &gt; 450 milliseconds (msec)

               -  PR interval &gt; 240 msec or QRS &gt; 110 msec

               -  Evidence of second- or third-degree atrioventricular (AV) block

               -  Pathological Q-waves (defined as Q-wave &gt;40 msec or depth &gt; 0.5 mV)

               -  Evidence of ventricular pre-excitation, complete left bundle branch block, right
                  bundle branch block (RBBB), or incomplete RBBB

               -  With a resting heart rate outside the range of 45 to 85 beats per minute (bpm)

          -  Abnormalities on physical examination, vital signs, ECG, or clinical laboratory
             values, unless those abnormalities were judged clinically insignificant by the
             investigator.

          -  Oxygen saturation (SpO2) ≤ 94% as measured by pulse oximetry.

          -  Refusal to abstain from caffeine or xanthine containing beverages entirely during
             confinement.

          -  Refusal to abstain from consumption of alcoholic beverages 48 hours prior to initial
             study drug administration and any time during study.

          -  History of smoking or use of nicotine products within 45 days of study drug
             administration or a positive urine cotinine test

          -  Blood or blood products donated within 30 days prior to study drug administration or
             anytime during the study.

          -  Positive results of urine drug screen or alcohol screen.

          -  Positive results of hepatitis B surface antigen (HBsAg), hepatitis C antibody
             (anti-HCV).

          -  Positive naloxone challenge test.

          -  Presence of Gilbert's Syndrome, or any known hepatobiliary abnormalities.

          -  The investigator believes the subject to be unsuitable for reason(s) not specifically
             stated in the exclusion criteria.

          -  Subjects who have allergies or other contraindications to transdermal systems or patch
             adhesives.

          -  Clinically significant history of allergic reaction to wound dressings or elastoplast.

          -  Subjects with a dermatological disorder at any relevant patch application site that
             precludes proper placement and/or rotation of patch.

          -  Taking antihistamines within 72 hours prior to dosing or systemic or topical
             corticosteroids within 3 weeks prior to dosing.

          -  Subjects will not allow hair to be removed at the proposed patch application site
             which may prevent proper placement of the patch.

          -  Subjects for whom a proper assessment of possible application site reactions would be
             confounded by local skin conditions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PPD Phase I Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>December 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <last_update_submitted>December 2, 2013</last_update_submitted>
  <last_update_submitted_qc>December 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy subjects</keyword>
  <keyword>Opioid</keyword>
  <keyword>Transdermal</keyword>
  <keyword>ECG</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 20, 2017</submitted>
    <returned>July 18, 2017</returned>
    <submitted>August 3, 2017</submitted>
    <returned>February 9, 2018</returned>
    <submitted>February 26, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

